Department of Radiation Oncology, Kindai University Faculty of Medicine, 377-2 Onohigashi, Osakasayama, Osaka, Japan.
Esophagus. 2019 Oct;16(4):371-376. doi: 10.1007/s10388-019-00675-y. Epub 2019 May 20.
We retrospectively compared the 7th and the 8th editions of The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification in the cohort of survival of the patients with esophageal squamous cell carcinoma (ESCC) treated by definitive radiotherapy.
We included in this study 403 patients with ESCC who underwent radiotherapy or chemoradiotherapy, at a total radiation dose of ≥ 50 Gy with curative intent from 2000 to 2016 at Kindai University Hospital, and who had no distant metastasis (excluding supraclavicular lymph node). The same patient data set was re-staged according to both the 7th and 8th editions of AJCC/UICC TNM classification.
For the 7th edition, 5-year overall survival (OS) for stages I, II, III, and IV were 58%, 52%, 22%, and 12%, respectively, which seemed to be separable into two groups (Stages I-II and III-IV). In the 8th edition, corresponding values for stages I, II, III, and IV were 65%, 44%, 34%, and 16%, respectively, which seemed to be separated into three groups (Stage I, II-III, and IV).
The 8th edition of AJCC/UICC TNM classification is a useful predictor of OS among ESCC patients who were treated with definitive radiotherapy.
我们回顾性比较了第 7 版和第 8 版美国癌症联合委员会/国际癌症控制联盟（AJCC/UICC）TNM 分期系统在接受根治性放疗的食管鳞癌（ESCC）患者生存队列中的表现。
我们纳入了本研究 403 例 ESCC 患者，这些患者于 2000 年至 2016 年在金泽大学医院接受了根治性放疗或放化疗，总放疗剂量≥50Gy，且无远处转移（不包括锁骨上淋巴结）。根据第 7 版和第 8 版 AJCC/UICC TNM 分期系统，对同一组患者数据进行重新分期。
第 7 版分期中，I 期、II 期、III 期和 IV 期的 5 年总生存率（OS）分别为 58%、52%、22%和 12%，似乎可以分为两组（I 期和 II 期，III 期和 IV 期）。第 8 版分期中，I 期、II 期、III 期和 IV 期的相应生存率分别为 65%、44%、34%和 16%，似乎可以分为三组（I 期、II-III 期和 IV 期）。
第 8 版 AJCC/UICC TNM 分期系统是预测接受根治性放疗的 ESCC 患者 OS 的有效指标。
